Breakthrough Drug That Muffles Your Cravings and Addictions

A hand reaching for pills next to a syringe and powder on a table

A diabetes drug that also kills cravings for alcohol, opioids, cocaine, and nicotine sounds like a pharmaceutical unicorn — but a study of more than 600,000 veterans suggests it might be real.

Quick Take

A large study published in the BMJ found glucagon-like peptide-1 (GLP-1) receptor agonist drugs were associated with significantly lower risks of developing substance use disorders across every major addictive substance.
Veterans taking GLP-1 drugs saw roughly 30% fewer drug-related emergency room visits and meaningfully lower rates of overdose compared to veterans on a different diabetes medication class.
The study is observational, not a randomized trial, meaning the association is compelling but causation has not been proven.
Researchers and clinicians are calling for randomized controlled trials to determine whether the craving-reduction effect is real and whether these drugs could be formally deployed against addiction.

The Numbers Behind the Headline

Researchers at Washington University in St. Louis analyzed a cohort of more than 600,000 United States veterans with type 2 diabetes, comparing those who started glucagon-like peptide-1 (GLP-1) receptor agonists — drugs like semaglutide, sold under brand names Ozempic and Wegovy — against those who started a different drug class called sodium-glucose cotransporter-2 (SGLT-2) inhibitors. The results, published in the BMJ, showed hazard ratios below 1.0 across every major substance category tested. ^[2]

The specific numbers are worth sitting with. GLP-1 users showed a 20% lower risk of developing alcohol use disorder, 25% lower risk for opioid use disorder, and 20% lower risk for cocaine use disorder compared to the SGLT-2 group. ^[2] Nicotine and cannabis use disorder risks also dropped. Among veterans who already had a substance use disorder before the study began, GLP-1 users experienced roughly 30% fewer drug-related emergency room visits in the three years following drug initiation. ^[1] That is not a rounding error.

Why Scientists Think GLP-1 Drugs Might Affect Addiction

The proposed mechanism centers on how GLP-1 receptor agonists interact with the brain’s reward circuitry. These drugs appear to dampen dopamine-driven reward signaling — the same pathway hijacked by addictive substances. When food loses some of its reward pull, which is why patients eat less, the theory is that alcohol, nicotine, and opioids may lose some of their pull as well. ^[3] Anecdotal reports from patients on semaglutide describing reduced urges to drink or smoke had already circulated for years before this study formalized the signal. ^[1]

The honest caveat is that the BMJ paper itself does not include craving scales, dopamine measurements, or neuroimaging. ^[2] The researchers observed outcomes — fewer diagnoses, fewer overdoses, fewer emergency visits — but did not directly measure what was happening in the brain. The mechanism remains biologically plausible and increasingly well-supported by animal studies, but direct human mechanistic evidence is still in development. Calling this proven neuroscience would be premature. Calling it a strong signal worth urgent investigation is entirely reasonable.

What the Study Cannot Tell You

The cohort was overwhelmingly older white men — the average age was 65, and the population was drawn entirely from the Veterans Affairs health system. ^[1] That is a specific group with specific health histories, prescribing patterns, and social circumstances. Whether the same association holds in younger populations, women, Medicaid recipients, or people without diabetes is genuinely unknown. Researchers used an active comparator design rather than random assignment, which reduces but does not eliminate the possibility that people who were prescribed GLP-1 drugs differed from the comparison group in ways that influenced addiction outcomes. ^[2]

Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose

A massive study of more than 600,000 U.S. veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight loss—they could also fight addiction…

— The Something Guy 🇿🇦 (@thesomethingguy) June 3, 2026

The absolute risk differences, while statistically meaningful, are also modest in scale. The composite reduction in new substance use disorders over three years was approximately 6.6 fewer cases per 1,000 people. ^[2] That matters enormously at a population level — multiply it across millions of prescriptions — but it is not a dramatic individual-level guarantee. The study authors were appropriately measured, describing their findings as suggesting a potential role that warrants further evaluation rather than declaring a breakthrough. ^[2] Media coverage has not always preserved that nuance. ^[3]

The Addiction Treatment Gap Makes This Research Urgent

Here is the context that makes this finding genuinely important regardless of its limitations. An estimated 98% of people with alcohol use disorder in the United States never receive any of the Food and Drug Administration (FDA)-approved medications for that condition. ^[1] The Substance Abuse and Mental Health Services Administration (SAMHSA) national helpline fields millions of calls annually from people and families in crisis who have exhausted conventional options. ^[4] Opioid overdose deaths remain near record levels. Against that backdrop, a widely prescribed, already-approved medication class showing a consistent cross-substance protective signal deserves serious and fast-tracked scientific attention, not cautious dismissal.

The case for randomized controlled trials is not a reason to ignore this data — it is the logical next step the data demands. If GLP-1 drugs genuinely reduce addiction risk and overdose outcomes even partially, the public health implications would rival almost any pharmacological discovery of the past two decades. The veterans in this study may have stumbled onto something the rest of medicine needs to catch up with quickly. ^[5]